Abeona Therapeutics Inc. (ABEO)

Abeona Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	3.5	1.41	3	10
Revenue Growth (YoY)	-	147.53%	-52.87%	-70.00%	-
Cost of Revenue	34.36	32.7	29.42	38.73	30.14
Gross Profit	-34.36	-29.2	-28	-35.73	-20.14
Selling, General & Admin	29.85	19	17.26	21.64	23.78
Operating Expenses	29.85	19	17.26	21.64	28.37
Operating Income	-64.21	-48.2	-45.26	-57.37	-48.5
Interest Expense	-4.21	-0.42	-0.74	-3.66	-4.12
Interest & Investment Income	4.25	2.12	0.43	0.04	1.3
Other Non Operating Income (Expenses)	0.44	-8.71	11.66	0.02	-
EBT Excluding Unusual Items	-63.74	-55.21	-33.9	-60.97	-51.32
Impairment of Goodwill	-	-	-	-32.47	-
Gain (Loss) on Sale of Assets	0	-0.05	-0.14	-	-
Asset Writedown	-	1.07	-5.66	-	-32.92
Other Unusual Items	-	-	-	8.5	-
Pretax Income	-63.73	-54.19	-39.7	-84.94	-84.23
Net Income	-63.73	-54.19	-39.7	-84.94	-84.23
Preferred Dividends & Other Adjustments	-	-	3.78	-	-
Net Income to Common	-63.73	-54.19	-43.48	-84.94	-84.23
Shares Outstanding (Basic)	41	21	8	4	4
Shares Outstanding (Diluted)	41	21	8	4	4
Shares Change (YoY)	91.99%	171.96%	99.65%	6.24%	84.02%
EPS (Basic)	-1.55	-2.53	-5.53	-21.57	-22.73
EPS (Diluted)	-1.55	-2.53	-5.53	-21.57	-22.73
Free Cash Flow	-58.46	-37.34	-43.61	-69.82	-36.36
Free Cash Flow Per Share	-1.42	-1.75	-5.55	-17.73	-9.81
Gross Margin	-	-	-	-	-201.39%
Operating Margin	-	-1377.14%	-3200.64%	-1912.33%	-485.04%
Profit Margin	-	-1548.23%	-3074.82%	-2831.20%	-842.34%
Free Cash Flow Margin	-	-1066.86%	-3084.37%	-2327.20%	-363.55%
EBITDA	-62.21	-45.91	-42.16	-54.12	-43.92
D&A For EBITDA	2	2.29	3.09	3.25	4.59
EBIT	-64.21	-48.2	-45.26	-57.37	-48.5
Revenue as Reported	-	-	-	-	10

Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q